An important Primary Biliary Cholangitis Market research report is produced by taking into account every requirement that organizations need to meet in order to expand successfully. This market report forecasts the market size based on data on major retailer sales, industry growth by upstream and downstream factors, industry advancement, major players, market segments, and application. When creating the reliable Primary Biliary Cholangitis Market study, the goals of the marketing research are taken into consideration. A market segmentation analysis is conducted taking into account the currencies, pricing, years taken into consideration, geographic scope, and markets covered.

The steadfast Primary Biliary Cholangitis Market report includes primary, secondary, and advanced data regarding the state, trends, size, share, growth, and segments of the global market for the 2023–2030 forecast period. The research thoroughly examines competitor actions such as product launches, joint ventures, mergers, and acquisitions, and their corresponding impact on sales, revenue, import, export, and CAGR figures. The CAGR figure of the Primary Biliary Cholangitis Market document varies over the course of the market's projected term. The assessment of the new investment projects' odds is covered in the final section, along with general study findings.

Explore Further Details about This Research Primary Biliary Cholangitis Market Report https://www.databridgemarketresearch.com/reports/global-primary-biliary-cholangitis-market

Primary biliary cirrhosis is a chronic liver disease that produces inflammation, fibrosis, and bile duct obstruction, resulting in the loss of tiny bile ducts within the liver. Autoimmunity, infection, and/or genetic predisposition are all possible causes of primary biliary cirrhosis. Itching, osteoporosis, high blood cholesterol, and malabsorption of fat and fat-soluble vitamins are symptoms of primary biliary cirrhosis, which can progress to hepatomegaly and hyperpigmentation splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and might eventually lead the liver to stop functioning completely.

Data Bridge Market Research analyses that the primary biliary cholangitis market was valued at USD 784.81 million in 2021 and is expected to reach USD 1,744.47 million by 2029, registering a CAGR of 10.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Primary biliary cholangitis, also known as primary biliary cirrhosis, is a chronic liver condition in which the bile ducts are gradually damaged. PBC has no known treatment. To control symptoms and reduce the progression of PBC, doctors prescribe medication. Ursodiol aids in the removal of bile from the liver. In many cases, this medication improves liver function and slows the course of liver disease. If ursodeoxycholic acid (UDCA) is ineffective or cannot be tolerated, obeticholic acid is used alone or in combination with it. This treatment lowers bile production while increasing bile flow out of the liver. Other pharmacological choices are available depending on the individual circumstances of each patient and the existence of other medical disorders. If liver function continues to deteriorate after medical treatment, a liver transplant may be required.

Drivers

• Increasing prevalence of primary biliary cholangitis

The rising prevalence of primary biliary cholangitis across the globe is estimated to enhance the market's growth. Primary biliary cholangitis (PBC) is an uncommon disease that causes a persistent, progressive liver disorder. It primarily affects women and usually strikes between the ages of 30 and 60.  The tiny bile duct in the liver is usually affected by PBC. Primary biliary cholangitis is split into four phases: stage 1 (no scarring) to stage 4 (cirrhosis). A mix of causes, including autoimmune, genetic, and environmental factors, can cause PBC.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of primary biliary cholangitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the primary biliary cholangitis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of primary biliary cholangitis market. Rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.

Recent Development

• In May 2022, Intercept Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for treating patients suffering from primary biliary cholangitis (PBC) who have not achieved an adequate biochemical response to ursodeoxycholic acid.

Global Primary Biliary Cholangitis Market Scope

The primary biliary cholangitis market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Liver Transplantation
• Drug Therapy
• Ursodeoxycholic acid (UDCA)
• Obeticholic acid
• Fibrates
• Budesonide
• Others

Diagnosis

• Imaging Tests
• Magnetic resonance elastography (MRE)
• Magnetic resonance cholangiopancreatography (MRCP)
• Ultrasound
• FibroScan
• Blood Tests
• Cholesterol test
• Antibody tests
• Liver tests
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Some of the major players operating in the primary biliary cholangitis market are:

• Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)
• Allergan (Ireland)

Key Offerings:

• Past Market Size and Competitive Landscape (2018 to 2022)
• Past Pricing and price curve by region (2018 to 2022)
• Market Size, Share, Size & Forecast by different segment | 2023−2029
• Primary Biliary Cholangitis MarketDynamics – Growth Drivers, Restraints, Opportunities, and Key Trends by Region
• Market Segmentation – A detailed analysis by segment with their sub-segments and Region
• Competitive Landscape – Profiles of selected key players by region from a strategic perspective
• Competitive landscape – Market Leaders, Market Followers, Regional player
• Competitive benchmarking of key players by region
• PESTLE Analysis
• PORTER’s analysis
• Value chain and supply chain analysis
• Legal Aspects of Business by Region
• Lucrative business opportunities with SWOT analysis
• Recommendations

Browse Related Reports:

Smart Pills Market Size, Share Analysis Report
Asia-Pacific Smart Pills Market Size, Share, Growth Analysis
North America Smart Pills Market Size, Share, Growth
Europe Smart Pills Market Demand,Size ,Share, Industry
Automated Border Control Market Size, Analysis and Forecast
Asia-Pacific Automated Border Control Market Size, Share, Trends & Forecast
Europe Automated Border Control Market Size And Share Analysis Report,
North America Automated Border Control Market by Size, Share, Forecast, & Trends
Middle East and Africa Automated Border Control Market Size Report- Industry Growth Analysis
Plant-Based Egg Replacers Market Size, Industry Share Forecast
Middle East and Africa Plant-Based Egg Replacers Market Size, Share, Growth | Opportunities,
North America Plant-Based Egg Replacers Market Size, Share Analysis Report
Europe Plant-Based Egg Replacers Market Size, Share, Growth Analysis
Asia-Pacific Plant-Based Egg Replacers Market Size, Share, Growth
Cannabidiol Market Demand,Size ,Share, Industry
Europe Cannabidiol (CBD) Market Size, Analysis and Forecast
Middle East and Africa Cannabidiol (CBD) Market Size, Share, Trends & Forecast
North America Cannabidiol (CBD) Market Size And Share Analysis Report,
Asia-Pacific Cannabidiol (CBD) Market by Size, Share, Forecast, & Trends
U.S. Cannabidiol (CBD) Market Size Report- Industry Growth Analysis
Acute Myeloid Leukemia Market Size, Industry Share Forecast

About Data Bridge Market Research:

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email – corporatesales@databridgemarketresearch.com